A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Not all companies are created equal, and StockStory is here to surface the ones with real upside. That said, here are three cash-producing companies to avoid and some better opportunities instead.
RH (RH)
Trailing 12-Month Free Cash Flow Margin: 6.8%
Formerly known as Restoration Hardware, RH (NYSE:RH) is a specialty retailer that exclusively sells its own brand of high-end furniture and home decor.
Why Are We Hesitant About RH?
-
Flat sales over the last three years suggest it must innovate and find new ways to grow
-
Falling earnings per share over the last three years has some investors worried as stock prices ultimately follow EPS over the long term
-
7× net-debt-to-EBITDA ratio shows it’s overleveraged and increases the probability of shareholder dilution if things turn unexpectedly
At $180.31 per share, RH trades at 28.6x forward P/E. Check out our free in-depth research report to learn more about why RH doesn’t pass our bar.
L.B. Foster (FSTR)
Trailing 12-Month Free Cash Flow Margin: 8.4%
Founded with a $2,500 loan, L.B. Foster (NASDAQ:FSTR) is a provider of products and services for the transportation and energy infrastructure sectors, including rail products, construction materials, and coating solutions.
Why Do We Think Twice About FSTR?
-
Backlog failed to grow over the past two years, suggesting the company may need to tweak its product roadmap and go-to-market strategy
-
Earnings growth underperformed the sector average over the last five years as its EPS grew by just 1.2% annually
-
Underwhelming 3.9% return on capital reflects management’s difficulties in finding profitable growth opportunities
L.B. Foster’s stock price of $38.58 implies a valuation ratio of 21x forward P/E. If you’re considering FSTR for your portfolio, see our FREE research report to learn more.
BioMarin Pharmaceutical (BMRN)
Trailing 12-Month Free Cash Flow Margin: 6.9%
Pioneering treatments for conditions that often had no previous therapeutic options, BioMarin Pharmaceutical (NASDAQ:BMRN) develops and commercializes therapies that address the root causes of rare genetic disorders, particularly those affecting children.
Why Does BMRN Give Us Pause?
-
Costs have risen faster than its revenue over the last two years, causing its adjusted operating margin to decline by 4.8 percentage points
-
Low returns on capital reflect management’s struggle to allocate funds effectively
-
High net-debt-to-EBITDA ratio of 5× increases the risk of forced asset sales or dilutive financing if operational performance weakens
